Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design,
multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12
weeks in Asian men with signs and symptoms of benign prostatic hyperplasia.